US Patent 9,056,120: Lenalidomide MDS Claims, Expiration, Litigation and Generic Entry Risk

US Patent 9,056,120 protects methods of treating myelodysplastic syndromes with lenalidomide, including the dosing, cycling, oral capsule or tablet administration, combination treatment, transplant setting, and treatment of transfusion-dependent anemia in low- to intermediate-1-risk MDS. The patent is a method-of-use patent, not a composition-of-matter patent.

The patent’s commercial significance is narrower than its broadest claim language. Its principal enforceable value is concentrated in lenalidomide treatment of MDS at daily doses of 1 mg to 25 mg, particularly the 21-days-on/7-days-off regimen and the use of lenalidomide for transfusion-dependent anemia. The patent’s projected statutory expiration is in 2027, subject to any applicable patent-term adjustment or terminal-disclaimer effects.[1]

What drug does US Patent 9,056,120 cover?

The claimed compound is lenalidomide, the active pharmaceutical ingredient in Revlimid. Lenalidomide is an immunomodulatory drug developed by Celgene Corporation and now commercialized by Bristol Myers Squibb following BMS’s acquisition of Celgene.

The claims cover lenalidomide and its pharmaceutically acceptable salts, solvates and stereoisomers. In commercial practice, the relevant product is oral lenalidomide, primarily supplied in capsules.

Patent element	Covered subject matter
Active ingredient	Lenalidomide
Brand product	Revlimid
Therapeutic area	Myelodysplastic syndromes
Dosage range	About 1 mg to about 25 mg per day
Key schedule	21 consecutive days followed by seven days of rest
Cycle length	28 days
Route	Oral
Dosage forms	Capsule or tablet
Combination agents	Dexamethasone or azacitidine
Patient population	Previously untreated or previously treated MDS patients
Additional setting	Administration before, during or after hematopoietic-cell transplantation

The compound identity is central to claim construction. The supplied text omits the chemical structure after “having the formula.” Based on the patent’s subject matter, therapeutic indication and corresponding Revlimid development program, that structure is lenalidomide.

What are the independent claims in US Patent 9,056,120?

The patent has two principal independent method claims.

Claim 1: Broad MDS treatment claim

Claim 1 covers:

A patient with myelodysplastic syndrome;
Administration of lenalidomide;
A daily dose of about 1 mg to about 25 mg; and
Lenalidomide or a pharmaceutically acceptable salt, solvate or stereoisomer.

The claim is not limited to a particular cytogenetic abnormality, transfusion status, line of therapy, route, formulation or treatment schedule. Those limitations appear in dependent claims.

The broadest apparent scope reaches a method of treating MDS with lenalidomide at any daily dose within the claimed range. It includes both labeled and off-label MDS use, provided the accused regimen falls within the claim limitations.

Claim 28: Transfusion-dependent anemia claim

Claim 28 is narrower. It requires treatment of:

Transfusion-dependent anemia;
Due to low- or intermediate-1-risk MDS; and
With lenalidomide at about 1 mg to about 25 mg per day.

This claim tracks the commercial MDS indication for Revlimid more closely than claim 1. It is likely to be the most commercially relevant claim for the labeled MDS indication, particularly where the patient has transfusion-dependent anemia and low- or intermediate-1-risk disease.

How do claims 1 and 28 differ?

Issue	Claim 1	Claim 28
Disease	Myelodysplastic syndrome generally	Low- or intermediate-1-risk MDS
Anemia requirement	None expressly stated	Transfusion-dependent anemia required
Dose	About 1 mg to about 25 mg daily	About 1 mg to about 25 mg daily
Compound	Lenalidomide and specified forms	Lenalidomide and specified forms
Commercial relevance	Broad MDS treatment	Labeled MDS use more closely
Potential design-around	More difficult because disease scope is broad	Easier if anemia or risk category falls outside the claim

Claim 1 has broader disease coverage. Claim 28 has more specific clinical limitations but aligns more closely with the original FDA-approved MDS population.

What dependent claims protect dosing and treatment schedules?

Claims 13 through 23 and 39 through 49 protect dosing schedules and dose levels. The key regimen is 21 consecutive days of treatment followed by seven consecutive days of rest in a 28-day cycle.

The patent specifically recites the following daily doses:

2.5 mg;
5 mg;
10 mg;
15 mg;
20 mg; and
25 mg.

Claims 22 and 48 cover 5 mg to 25 mg daily for 21 days followed by seven days of rest. Claims 23 and 49 focus on 10 mg or 15 mg daily under that schedule.

Claim group	Main limitation
13, 39	Cyclical administration
14, 40	21 days of treatment and seven days of rest
15, 41	Continued cycles until progression or unacceptable toxicity
16, 42	About 2.5 mg daily
17, 43	About 5 mg daily
18, 44	About 10 mg daily
19, 45	About 15 mg daily
20, 46	About 20 mg daily
21, 47	About 25 mg daily
22, 48	5 mg to 25 mg for 21 of 28 days
23, 49	10 mg or 15 mg for 21 of 28 days

The claims use “about,” which introduces a scope-of-equivalency issue. The precise reach depends on claim construction, specification support, prosecution history and the ordinary meaning of the dose term in the relevant technical context. A regimen materially outside the stated range may still present risk under equivalents principles, although literal infringement would be less direct.

What formulations and routes are protected?

Claims 24 through 27 and 50 through 53 cover oral administration and oral dosage forms.

The claims specifically identify:

Oral administration;
Capsules;
Tablets;
Capsules containing 1 mg to 25 mg; and
Capsules containing 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg.

These claims are formulation and presentation claims in method-of-use form. They do not appear to claim a novel capsule composition independently of the MDS treatment method. A generic manufacturer that sells lenalidomide capsules for non-MDS indications may avoid these claims if its label omits the patented MDS use and its marketing conduct does not encourage that use.

A product label carve-out is therefore commercially important. Under the Hatch-Waxman framework, a generic applicant may omit a patented method of use from its labeling through a section viii statement when the remaining labeling does not require the patented indication.[2]

What combination therapies are covered?

Claims 9 through 11 and 35 through 37 cover administration of a second active agent. The claims identify:

Dexamethasone; and
Azacitidine.

The combination claims require more than concurrent availability of the two products. The accused method would generally need to involve administration of lenalidomide together with the second active agent in the claimed MDS treatment context.

These claims may have limited importance for standard MDS prescribing compared with the lenalidomide monotherapy claims. Azacitidine is an established MDS therapy, while dexamethasone is more closely associated with lenalidomide treatment in multiple myeloma. Commercial risk depends on the actual treatment protocol, label language and inducement evidence.

Does the patent cover transplant-related treatment?

Claims 12 and 38 cover administration of lenalidomide before, during or after transplantation involving:

Umbilical cord blood;
Placental blood;
Peripheral blood stem cells;
Hematopoietic stem-cell preparations; or
Bone marrow.

These claims extend the patent beyond routine outpatient MDS treatment. Their practical value is limited by the clinical frequency of transplant-based treatment in the specific claimed setting and by the requirement that lenalidomide administration be connected to the transplant course.

The claims do not independently claim the transplant procedure. They claim the administration of lenalidomide in temporal relation to the transplant.

How should claim 3 be interpreted?

As supplied, claim 3 contains the language that the compound “is and is not a pharmaceutically acceptable salt, solvate or stereoisomer.” That wording is internally defective if read literally. A compound cannot simultaneously be and not be the specified form in the same limitation.

The text likely reflects an omitted chemical structure or formatting error in the reproduced claim. The legally operative interpretation must be taken from the issued patent PDF, prosecution history and certified claim text. On the supplied wording alone, claim 3 presents an indefiniteness and claim-construction problem. It should not be treated as an independently reliable limitation without reviewing the issued patent record.

Claims 4 through 6 separately cover the compound as:

A pharmaceutically acceptable salt;
A pharmaceutically acceptable solvate; or
A pharmaceutically acceptable stereoisomer.

When does US Patent 9,056,120 lose exclusivity?

The patent’s projected expiration is in 2027, based on the patent family’s statutory term. The precise enforceable date should be determined from the USPTO Patent Center record, including any patent-term adjustment, terminal disclaimer and continuity data.[1]

Exclusivity component	Relevance to lenalidomide MDS
Lenalidomide composition patents	Earlier core exclusivity; largely expired or expiring before the MDS method estate
MDS method patents	Protect treatment of MDS with lenalidomide
Dosage-regimen patents	Protect specified dose and cycle schedules
Orange Book listings	Can support Hatch-Waxman notice and litigation if listed against the relevant product
FDA regulatory exclusivity	Distinct from patent exclusivity and generally expired for the original MDS approval
Generic approvals	Possible with paragraph IV certifications, settlements or use carve-outs

The patent does not create a new regulatory exclusivity period. It is a patent right and must be analyzed separately from FDA approval exclusivity.

What is the Orange Book status of this patent?

The Orange Book identifies patents submitted by a new drug application holder for an approved drug product. Patent listing is product- and NDA-specific. A method-of-use patent can be listed when it claims an approved method of using the drug and satisfies FDA listing requirements.[3]

US Patent 9,056,120 should be evaluated against the Orange Book patent listing for Revlimid NDA 021880 and the relevant FDA patent-listing records. The commercial consequences depend on whether the patent was listed during the relevant ANDA certification period and whether it remained listed when the generic application was filed.

An Orange Book listing can trigger a 30-month stay after a timely patent-infringement action following a paragraph IV notice. A patent that is not listed may still be enforceable, but it does not create the same automatic Hatch-Waxman stay mechanism.

What Paragraph IV challenges affect lenalidomide?

Lenalidomide generic applicants have used the Hatch-Waxman framework to challenge Revlimid patents and negotiate limited-entry settlements. The principal challenge mechanisms are:

Paragraph IV certifications asserting that listed patents are invalid, unenforceable or not infringed;
Section viii statements carving out patented methods of use;
Declaratory and infringement litigation involving listed method, formulation or distribution patents; and
Settlement agreements establishing permitted generic-entry dates and supply restrictions.

Generic lenalidomide entered the US market through settlement-based and authorized-entry arrangements before the full expiration of every later-expiring Revlimid patent. The existence of generic product does not mean that all Revlimid patents were invalidated. Entry can occur with a restricted label, a negotiated date or an agreement not to market certain indications.

For US Patent 9,056,120, the key question is whether a generic label includes the MDS indication or otherwise encourages the claimed 21-day dosing regimen. A generic that excludes MDS from its label presents a weaker induced-infringement case than a product labeled for transfusion-dependent anemia due to low- or intermediate-1-risk MDS.

Which companies have challenged Revlimid patents?

Known generic and potential generic participants in the lenalidomide market have included Teva, Natco, Dr. Reddy’s Laboratories, Cipla, Zydus and other ANDA sponsors. Teva and Natco have had a particularly important commercial relationship in US generic lenalidomide supply.

The relevant legal landscape includes:

Company or group	Role in the market
Bristol Myers Squibb/Celgene	Revlimid patent holder and NDA sponsor
Teva	Generic lenalidomide supplier and ANDA participant
Natco	Generic development and supply partner
Dr. Reddy’s Laboratories	Generic lenalidomide applicant and marketer
Cipla	Generic lenalidomide market participant
Zydus	Generic lenalidomide applicant or supplier
FDA	ANDA approval and labeling authority
USPTO	Patent examination, term and ownership records

The existence of a settlement does not establish patent validity. Most Hatch-Waxman disputes end through negotiated market-entry terms rather than a final merits judgment.

What is the litigation status of US Patent 9,056,120?

The patent should be treated as part of the broader Revlimid patent estate rather than as an isolated right. Litigation risk depends on four issues:

Whether the patent was listed for the relevant Revlimid NDA;
Whether an ANDA applicant certified paragraph IV against it;
Whether the generic label includes MDS or a covered method; and
Whether the parties resolved the dispute through a settlement.

Generic launch alone does not necessarily infringe claims 1 or 28. A generic company can reduce risk through a section viii carve-out, provided its label and commercial conduct do not encourage use for the carved-out indication.

Potential litigation theories include:

Direct infringement by practicing the MDS treatment method;
Induced infringement based on prescribing information, promotional material or distribution conduct;
Contributory infringement involving capsules supplied for the claimed use; and
Invalidity challenges based on anticipation, obviousness, written description or indefiniteness.

The claim language creates vulnerability around broad MDS treatment, overlapping prior art and the internal wording of claim 3. The more specific claims directed to transfusion-dependent anemia, defined dosing and the 21/7 cycle may have stronger fact-based infringement positions but narrower coverage.

How strong is the patent estate for lenalidomide MDS?

The estate is strongest when the commercial facts match the patent’s most specific clinical limitations.

Estate component	Relative strength	Reason
Broad MDS treatment claim	Moderate	Broad coverage but greater prior-art and claim-construction exposure
Transfusion-dependent anemia claim	Moderate to strong	Closely aligned with the approved MDS use
21/7 dosing claims	Stronger for matching regimens	Clear clinical and label-specific limitations
Dose-specific claims	Moderate	Easier to prove when product labeling specifies the dose
Oral capsule claims	Moderate	Relevant to commercial product presentation
Combination claims	Variable	Depends on actual prescribing protocol
Transplant claims	Narrower	Limited to transplant-associated administration
Claim 3	Weak on supplied text	Apparent internal inconsistency

The strongest enforcement position generally arises where a product label expressly identifies MDS, transfusion-dependent anemia, low- or intermediate-1-risk disease, and a 21-day treatment cycle.

What generic launch risks exist?

Generic entry risk is divided between regulatory launch and practical infringement exposure.

Scenario 1: Full MDS label

A generic with a full MDS indication would face the highest risk under claims 1 and 28. The label could directly communicate the patented method, creating potential induced-infringement allegations.

Scenario 2: Section viii carve-out

A generic may omit MDS from its label while retaining non-MDS indications such as multiple myeloma. This reduces label-based infringement risk but does not eliminate risk from:

Promotional statements;
Sales-force communications;
Clinical support materials;
Distribution practices; or
Other evidence showing intent to encourage MDS use.

Scenario 3: Post-expiration launch

After the relevant patent expiration date, a generic can market for the covered MDS use without that patent creating a remaining exclusionary right. Other patents, regulatory requirements, controlled-distribution obligations and contractual restrictions may still affect market access.

Scenario 4: Settlement-based entry

A generic may launch before expiration under a settlement permitting entry on a specified date or subject to supply, indication or manufacturing restrictions.

Is there biosimilar risk?

There is no biosimilar risk in the technical sense. Lenalidomide is a synthetic small molecule, not a biologic. Competition proceeds through the ANDA generic-drug pathway rather than the abbreviated biologics license application pathway.

The relevant competitive threats are:

Authorized generic supply;
ANDA-approved generic lenalidomide;
Paragraph IV challenges;
Section viii label carve-outs; and
Settlement-based limited launches.

How does US Patent 9,056,120 compare with core lenalidomide patents?

Patent type	What it protects	Strategic effect
Composition-of-matter patent	Lenalidomide molecule	Broadest product protection, generally earliest expiration
Salt, polymorph or formulation patent	Physical form or dosage formulation	Can complicate substitution and manufacturing
MDS method patent	Use of lenalidomide to treat MDS	Relevant to labeled indication
Dose-regimen patent	Dose and 21/7 schedule	Targets clinical practice and product labeling
Distribution patent	Dispensing controls or risk-management system	May affect commercial launch logistics
Manufacturing patent	Synthesis or process steps	Can create supply-chain barriers without blocking all finished-product manufacture

US Patent 9,056,120 is commercially important because it protects use rather than the molecule itself. A generic may be able to manufacture and sell lenalidomide for unpatented indications while excluding the patented MDS use.

What licensing and settlement arrangements affect the market?

Celgene and later Bristol Myers Squibb entered into licensing, supply and settlement arrangements with generic companies that permitted staged US entry for lenalidomide. These arrangements helped define when and how generic manufacturers could enter before the expiration of later Revlimid patents.

The critical commercial terms in this type of agreement are:

Earliest permitted launch date;
Authorized or independent generic status;
Royalty obligations;
Volume limits;
Indication carve-outs;
API or finished-dose supply rights;
Geographic restrictions; and
Treatment of later-issued or later-listed patents.

Settlement terms are often confidential or distributed across multiple agreements. They should not be inferred solely from the generic product’s FDA approval date.

What is the FDA regulatory status of Revlimid for MDS?

The FDA approved Revlimid for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q abnormality, with or without additional cytogenetic abnormalities.[4] The approved indication is narrower than claim 1 of US Patent 9,056,120.

The patent claims cover broader MDS categories, including refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation and chronic myelomonocytic leukemia. Some of these terms reflect older disease-classification terminology.

FDA-approved labeling and patent scope must be analyzed separately:

The FDA label defines the approved use;
The patent defines the exclusionary claim scope;
A patented method can extend beyond the labeled indication; and
An approved generic may omit the patented indication through a label carve-out.

What revenue exposure does this patent create?

The direct revenue exposure is concentrated in Revlimid sales for MDS, not the entire lenalidomide market. Revlimid generated multibillion-dollar annual sales before broad generic entry, with multiple myeloma accounting for the majority of revenue. MDS represented a smaller but commercially important indication.

A generic that launches only with non-MDS indications can erode multiple-myeloma revenue while leaving some MDS revenue protected through labeling and prescribing controls. A full-label MDS generic creates greater exposure because it competes directly for the indication most closely aligned with claims 1 and 28.

Revenue impact depends on:

Generic launch date;
Number of approved manufacturers;
Allowed strengths;
MDS label inclusion;
Payer substitution;
Authorized-generic strategy;
Revlimid distribution restrictions; and
Remaining patents outside US Patent 9,056,120.

Key Takeaways

US Patent 9,056,120 is a lenalidomide method-of-use patent for MDS.
Claims 1 and 28 are the principal independent claims.
Claim 1 broadly covers MDS treatment at about 1 mg to about 25 mg daily.
Claim 28 focuses on transfusion-dependent anemia due to low- or intermediate-1-risk MDS.
The patent specifically protects 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg doses.
The 21-days-on/7-days-off schedule is a central dependent-claim limitation.
Oral capsules and tablets are expressly covered in dependent claims.
Dexamethasone and azacitidine combination treatment is included.
The projected statutory expiration is in 2027, subject to the official USPTO term record.
Generic manufacturers can reduce risk through section viii MDS-label carve-outs.
No biosimilar pathway applies because lenalidomide is a small molecule.
Claim 3, as reproduced, contains an apparent internal inconsistency and requires review against the issued patent record.
The highest commercial risk arises from a generic carrying an MDS indication and the 21/7 treatment schedule.

FAQs About US Patent 9,056,120 and Lenalidomide

Does US Patent 9,056,120 cover Revlimid for multiple myeloma?

No. The claims supplied are directed to treatment of MDS and MDS-related transfusion-dependent anemia. They do not expressly claim multiple-myeloma treatment.

Can a generic sell lenalidomide before the patent expires?

Yes, a generic may enter through a settlement, authorized-generic arrangement or a label that excludes the patented MDS use. Entry does not necessarily authorize use for every patented indication.

Does the patent cover lenalidomide tablets?

Yes, dependent claims expressly recite oral administration in capsule or tablet form. The claim remains tied to treatment of the specified MDS conditions.

Can a physician prescribe generic lenalidomide for MDS after a section viii carve-out?

The prescribing decision is separate from the generic’s FDA label. A carved-out label reduces the manufacturer’s label-based infringement exposure but does not automatically eliminate all potential inducement issues.

Is the 21/7 regimen required for every claim?

No. Claims 1 and 28 cover the stated daily dose range without expressly requiring the 21/7 cycle. The 21/7 schedule is added by dependent claims 14, 22, 23, 40, 48 and 49.

References

United States Patent and Trademark Office. (2015). US Patent No. 9,056,120, methods of treating myelodysplastic syndromes.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Act.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (n.d.). Revlimid (lenalidomide) prescribing information. Bristol-Myers Squibb Company.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E390135	⤷ Start Trial
Australia	2003228508	⤷ Start Trial
Australia	2008202638	⤷ Start Trial
Australia	2011253161	⤷ Start Trial
Australia	2012201727	⤷ Start Trial
Australia	2014202561	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,056,120

Summary for Patent: 9,056,120